Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse

#ZYME Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

www.stocktitan.net/news/ZYME/zymeworks-anno...

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing Zymeworks (NASDAQ: ZYME) entered a $250 million non-recourse, royalty-backed note financing with Royalty Pharma on March 2, 2026. Repayments come from 30% of worldwide tiered royalties on Ziihera until repaid; Zymeworks retains 70% of royalties during repayment.Royalty Pharma stops receiving payments after cumulative receipts of 1.65x the note by December 31, 2033 or 1.925x thereafter. Proceeds are non-dilutive, support share repurchases, potential strategic acquisitions, and extend cash runway beyond 2028. Zymeworks keeps up to $1.5 billion in remaining milestone payments tied to Ziihera.

#ZYME Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

www.stocktitan.net/news/ZYME/zymeworks-and-...

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results Supplemental Biologics License Application for Ziihera ® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) during 1Q 2026 in the U.S. with potential launch in 2H 2026 Up to $440.0 million in milestone payments eligible

#ZYME Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/ZYME/zymeworks-prov...

Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy Zymeworks (Nasdaq: ZYME) announced board and leadership changes effective January 12, 2026 and early 2026 to align with its updated corporate strategy. Brian Cherry was appointed to the Board, bringing private equity and M&A experience. Mark Hollywood is promoted to Executive Vice President and Chief Operating Officer with expanded responsibilities. Dr. Sabeen Mekan will become Senior Vice President and Chief Medical Officer on February 1, 2026; current CMO Dr. Jeff Smith will retire January 31, 2026 and serve as an adviser during transition. The company initiated a search for a permanent CFO after departures in Q1 2026; Kenneth Galbraith is Acting CFO.

#ZYME Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

www.stocktitan.net/news/ZYME/zymeworks-anno...

Zymeworks Outlines Strategic Priorities and Outlook for 2026 Zymeworks (Nasdaq: ZYME) outlined strategic priorities for 2026, highlighting positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2+ gastroesophageal adenocarcinoma and a planned supplemental BLA submission in 1H-2026. Key financials: potential regulatory milestones of $440.0M (US $250M, EU $100M, Japan $75M, China $15M), cash and marketable securities of approximately $270.6M as of Dec 31, 2025, and a $125.0M authorized share repurchase program (≈$19.0M used to date). Guidance includes ~$300.0M of adjusted gross operating expense (non-GAAP) over 2026–2028 and an expectation that cash plus anticipated milestones could fund operations beyond 2028.

#ZYME Zymeworks Outlines Strategic Priorities and Outlook for 2026

www.stocktitan.net/news/ZYME/zymeworks-outl...

BREAKING NEWS: ( NASDAQ: #ZYME ) Overweight Recommendation Issued On ZYME By Wells Fargo

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets Zymeworks (NASDAQ: ZYME) announced a strategic initiative to optimize value from licensed products by building a diversified portfolio of revenue-generating healthcare assets while retaining in-house R&D capabilities.Key elements: potential near-term Ziihera GEA regulatory milestones of $440.0M, pasritamig milestones of $434.0M plus royalties, a new $125.0M share repurchase authorization, and reported cash, cash equivalents and investments of $299.4M as of Sept 30, 2025.

#ZYME Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

www.stocktitan.net/news/ZYME/zymeworks-anno...

Just In: ( NASDAQ: #ZYME ) ZYME Price Target Alert: $37.00. Issued by Leerink Partners

NEWS: ( NASDAQ: #ZYME ) Zymeworks Inc. (NASDAQ: ZYME) Sets New 52-Week High in Monday Session

Most Searched, Monday November 17, 2025 – Crystal Equity Research

Most searched small-cap stocks, Mon Nov 17th - #RXRX #LAC #SGBX #HIVE #ANVS #SGML #IVVD #DNN #LAES #CYPH #ZYME #WRD #QUBT #PLUG #PEBO #ONDS #OBE #ESPR #CLSK #AI - More: crystalequityresearch.com/most-searche... - #smallcap

#JAZZ = +22% #ZYME = +35%

Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results

#ZYME Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/ZYME/zymeworks-prov...

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference Zymeworks (NASDAQ: ZYME) reported preliminary Phase 1 clinical data for ZW191, an antibody-drug conjugate targeting folate receptor-α, presented Oct 23, 2025. As of Sep 10, 2025, 41 patients were enrolled (doses 1.6–11.2 mg/kg) with 85% remaining on treatment.Key efficacy: among response-evaluable patients (n=27) overall ORR 44%; at 6.4–9.6 mg/kg ORR 53%. In gynecological cancers (n=24) ORR was 50% overall and 64% at 6.4–9.6 mg/kg. Responses began at 3.2 mg/kg and occurred with low/negative FRα expression.Safety and next steps: no serious treatment-related AEs, discontinuations for AEs, or deaths reported. Common Grade ≥3 treatment-related AEs: anemia 10%, neutropenia 5%, thrombocytopenia 5%. MTD determined at 11.2 mg/kg; dose-optimization cohorts at 6.4 mg/kg and 9.6 mg/kg planned (~30 patients each) with dose optimization to start in 4Q-2025.

#ZYME Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

www.stocktitan.net/news/ZYME/zymeworks-pres...

Clinical Development Ends: Zymeworks' Cancer Drug ZW171 Shows Concerning Safety Profile in Phase 1 Biotech firm Zymeworks stops ZW171 development after Phase 1 trial reveals dose-limiting toxicities. Company shifts focus to pipeline including ZW191, ZW251, and planned 2026 IND for ZW209.

#ZYME Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

www.stocktitan.net/news/ZYME/zymeworks-anno...

Leading Indicators, Thursday August 21, 2025 – Crystal Equity Research

Small-cap stocks with improving money flow, Thu Aug 21st - #ZYME #TRST #SENEA #PHVS #MRCC #IMRX #HOPE #VALN #EDUC #CRON #SVV #HRTG #FFWM #CATO - More: crystalequityresearch.com/leading-indi... - #smallcap

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#NVDA, #META, #ZETA, #AVGO, #ZYME

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#ZETA, #LFMD, #ZYME, #SEI, #LCID

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #ZETA 5.8x
2. #LFMD 3.1x
3. #ZYME 3.1x
4. #METC 3.0x
5. #SEI 2.9x

#OptionFlow #OptionsTrading #Trading

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate Zymeworks (NASDAQ:ZYME) announced FDA clearance of its Investigational New Drug (IND) application for ZW251, a novel antibody-drug conjugate (ADC) targeting hepatocellular carcinoma (HCC). ZW251 is designed to target glypican-3 (GPC3), which is expressed in over 75% of HCC cases.The drug represents Zymeworks' second ADC utilizing their proprietary topoisomerase 1 inhibitor payload. Preclinical studies demonstrated strong anti-tumor activity across various HCC models and favorable tolerability in non-human primates at doses up to 120 mg/kg. The company plans to initiate Phase 1 clinical trials in 2025.

#ZYME Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

www.stocktitan.net/news/ZYME/zymeworks-anno...

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference Zymeworks (NASDAQ: ZYME) presented preclinical data for ZW1528, its novel IL-4Rα x IL-33 bispecific molecule targeting respiratory inflammation, at the American Thoracic Society International Conference. The data showed ZW1528's high-affinity binding to both IL-33 and IL-4Rα, effectively blocking IL-4, IL-13, and IL-33 signaling pathways. Key findings demonstrated efficacy in murine models of lung inflammation, extended pharmacokinetics, and biophysical stability at high concentration (150 mg/mL). The company expects to file regulatory submissions for Phase 1 studies in 2H-2026. Additionally, Zymeworks is developing ZW1572 for atopic dermatitis and plans further IND submissions for 2028 and beyond.

#ZYME Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

www.stocktitan.net/news/ZYME/zymeworks-pres...

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results Zymeworks (NASDAQ: ZYME) reported its Q1 2025 financial results and corporate updates. The company presented six posters at AACR showcasing their multispecific T cell engager and antibody-drug conjugate platforms. They appointed Dr. Sabeen Mekan as SVP of Clinical Development. Financial highlights include $321.6M in cash resources (vs $324.2M in Dec 2024), with runway into 2H-2027. Q1 revenue was $27.1M (vs $10.0M in Q1 2024), including milestone payments from GSK ($14M) and Daiichi Sankyo ($3.1M). Net loss decreased to $22.6M from $31.7M year-over-year. Their partner Jazz reported $2.0M in Ziihera® sales, generating $0.2M in royalties for Zymeworks. The company continues to advance its pipeline in cancer, inflammation, and autoimmune diseases.

#ZYME Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/ZYME/zymeworks-prov...

#deusex #zyme #messyouup #pcgaming #gaming

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results Zymeworks (NASDAQ: ZYME) reported key developments and financial results for Q4 and full-year 2024. The company achieved significant milestones, including the FDA accelerated approval of Ziihera® for HER2-positive biliary tract cancer and initiation of first-in-human studies for two pipeline products: ZW191 and ZW171.Financial highlights include $324.2 million in cash resources as of December 31, 2024, with projected runway into 2H-2027. Revenue was $76.3 million in 2024, including a $25 million milestone payment from Jazz for Ziihera's approval. The company reported a net loss of $122.7 million for 2024.Key pipeline updates include: accelerated IND submission timeline to mid-2025 for ZW251 (targeting GPC3), ongoing Phase 1 trials for ZW191 in FR⍺-expressing tumors and ZW171 in advanced cancers, and paused development of ZW220. Ziihera® achieved initial sales of $1.1 million in December 2024 following FDA approval.

#ZYME Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/ZYME/zymeworks-prov...

GSK Partnership Pays Off: How Zymeworks Just Unlocked $14 Million in Clinical Milestone Revenue Biotech firm receives significant cash milestone from GSK collaboration, marking important clinical progress in their partnership developing novel biotherapeutics.

#ZYME Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

www.stocktitan.net/news/ZYME/zymeworks-anno...

Zymeworks Unveils 2025 Pipeline Strategy: Multiple INDs Planned, $324M Cash Position Supports Growth Zymeworks outlines ambitious 2025-2026 pipeline expansion with 4 new IND submissions planned. Strong $324M cash position extends runway to 2027, backed by recent FDA approval.

#ZYME Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

www.stocktitan.net/news/ZYME/zymeworks-outl...

#ZYME Zymeworks Announces Participation in Upcoming Investor Conferences

www.stocktitan.net/news/ZYME/zymeworks-anno...